Skip to content
Richard Peek
Richard Peek
  • Home
  • Contact Me
  • Publications
  • Richard Peek
← P160 SERUM ALBUMIN WEEK 6/WEEK 0 RATIO AFTER ANTI-TNF BEST PREDICTS BOTH SHORT- AND LONG-TERM CLINICAL OUTCOMES IN ANTI-TNF-NAïVE ULCERATIVE COLITIS PATIENTS
Hepatitis B Virus Infection and Hepatitis C Virus Treatment in a Large Cohort of Hepatitis C–Infected Patients in the United States →

P155 REAL-WORLD SAFETY OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A META-ANALYSIS

Posted on January 18, 2018 by Gastroenterology Journal

Vedolizumab (VDZ) is used to treat Crohn’s disease (CD) and ulcerative colitis (UC). Data from large real-world (RW) cohorts can further characterize safety events not fully elucidated in clinical trials.

This entry was posted in News. Bookmark the permalink.
← P160 SERUM ALBUMIN WEEK 6/WEEK 0 RATIO AFTER ANTI-TNF BEST PREDICTS BOTH SHORT- AND LONG-TERM CLINICAL OUTCOMES IN ANTI-TNF-NAïVE ULCERATIVE COLITIS PATIENTS
Hepatitis B Virus Infection and Hepatitis C Virus Treatment in a Large Cohort of Hepatitis C–Infected Patients in the United States →
  • Links

    • Gastroenterology
    • MyVUMC
  • January 2018
    S M T W T F S
     123456
    78910111213
    14151617181920
    21222324252627
    28293031  
    « Dec   Feb »
  • Other websites

    • Etiological Studies of Gastric Carcinoma
    • H. pylori and Gastric Cancer
Richard Peek
Proudly powered by WordPress.